A Phase 1b/2 Study of AZD9668, an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation

Trial Profile

A Phase 1b/2 Study of AZD9668, an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs AZD 9668 (Primary)
  • Indications Bronchiolitis obliterans
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 Oct 2017 Planned primary completion date changed from 30 Sep 2017 to 30 Sep 2018.
    • 16 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top